BriaCell Therapeutics Corp. (NASDAQ:BCTXW) Sees Significant Decline in Short Interest

BriaCell Therapeutics Corp. (NASDAQ:BCTXWGet Free Report) was the recipient of a large decline in short interest in January. As of January 31st, there was short interest totalling 1,000 shares, a decline of 47.4% from the January 15th total of 1,900 shares. Based on an average daily volume of 9,700 shares, the short-interest ratio is presently 0.1 days.

Institutional Investors Weigh In On BriaCell Therapeutics

A hedge fund recently bought a new stake in BriaCell Therapeutics stock. Sequoia Financial Advisors LLC acquired a new stake in shares of BriaCell Therapeutics Corp. (NASDAQ:BCTXWFree Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 45,000 shares of the company’s stock, valued at approximately $112,000.

BriaCell Therapeutics Trading Down 0.8 %

NASDAQ:BCTXW traded down $0.01 during mid-day trading on Monday, hitting $1.34. 1,231 shares of the company’s stock were exchanged, compared to its average volume of 9,272. BriaCell Therapeutics has a one year low of $0.71 and a one year high of $3.49. The business has a fifty day moving average price of $1.87 and a 200 day moving average price of $2.00.

About BriaCell Therapeutics

(Get Free Report)

BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers.

Featured Articles

Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with's FREE daily email newsletter.